2022 Fiscal Year Final Research Report
Association of nuclear beta-catenin and PD1/PDL1 expression with cancer stem niche in advanced rectal cancer
| Project/Area Number |
19K07421
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49020:Human pathology-related
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
三枝 信 北里大学, 医学部, 教授 (00265711)
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | 直腸癌 / NCRT / PD-L1 |
|---|
| Outline of Final Research Achievements |
We focused on the immunological impact of PD-1/PD-L1 signaling during tumor progression in colorectal carcinoma (CRC) and its association with resistance to neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal carcinoma (LAd-RC). Histopathological and immuno-histochemical analyses of 100 CRC cases (including 34 RC) without NCRT and 109 NCRT-treated LAd-RC cases were performed. A combination of stromal PD-L1+ immune cells and nuclear β-catenin+ tumor budding may contribute to tumor progression in CRC and resis-tancetoNCRTinLAd-RC, throughformation ofniche-like lesions that exhibit immune resistance and CSC properties.
|
| Free Research Field |
人体病理学
|
| Academic Significance and Societal Importance of the Research Achievements |
我が国の進行期直腸癌患者数は5万人で、その予後は術前化学・放射線療法（NCRT）と外科的切除の併用療法により著しく向上したが、依然、NCRT抵抗例も認められる。NCRT抵抗性を示す進行直腸癌では、間質のPD-L1陽性免疫細胞と癌幹細胞化特性を示すニッチ様病変がNCRTへの抵抗に寄与する可能性が示されたことから、NCRTと癌免疫療法の併用はNCRT抵抗性直腸癌の新規治療戦略への展開が期待でき、今後臨床試験などで検討される価値があると考えられた。
|
